CASE Ultra

QSAR software for modeling and predicting toxicity of chemicals

Licensing Options

Toxicity Assessments

ICH M7 models, Mutagenicity, Carcinogenicity, Cardiotoxicity, Hepatotoxicity, Skin and Eye toxicity, and many more

Learn more ›


Dual methodology support for compliance with ICH M7 guidelines

According to the ICH M7 guidelines, two complimentary QSAR methodologies (statistics based and expert rule based) should be used to evaluate the chemical's potential to cause bacterial mutagenicity. CASE Ultra has both methodologies built in for a complete ICH M7 compliant assessment.

Transparent and easy to understand test results

The test results generated by CASE Ultra speak the language of chemists and toxicologists. Identified alerts, their statistical parameters and the way they are used to get the final prediction call is explained clearly.

Essential in-silico tool for regulatory submission

CASE Ultra and many of its models are actively used and fully supported by US FDA and other regulatory agencies around the world.

Excellent test reports

Test results can be exported to properly formatted, clear and comprehensive reports. Report types include Word, Excel, Plain Text, QPRF.

Use CASE Ultra in drug discovery

CASE Ultra is being used by the pharma industry to screen drug candidates for potential toxicity at all stages of drug discovery.

User friendly interface

Being such a sophisticated scientific software, CASE Ultra is very user friendly. You can work with the most advanced features using just a few clicks with minimal or no training.

Great for research & education

CASE Ultra is an excellent tool for building predictive models and exploring the underlying mechanisms of biological activity of chemicals, pharmaceuticals, their impurities and metabolites. It is currently being used in universities for this purpose.